Lantern Pharma, Inc. (LTRN)
1.80
-0.04
(-2.17%)
USD |
NASDAQ |
Sep 09, 13:39
Lantern Pharma Enterprise Value : 16.16M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 16.16M |
| September 04, 2026 | 16.98M |
| September 03, 2026 | 16.54M |
| September 02, 2026 | 17.30M |
| September 01, 2026 | 18.45M |
| August 31, 2026 | 18.58M |
| August 28, 2026 | 19.09M |
| August 27, 2026 | 20.24M |
| August 26, 2026 | 20.49M |
| August 25, 2026 | 20.49M |
| August 24, 2026 | 19.60M |
| August 21, 2026 | 22.53M |
| August 20, 2026 | 21.90M |
| August 19, 2026 | 24.45M |
| August 18, 2026 | 24.83M |
| August 17, 2026 | 25.85M |
| August 14, 2026 | 26.49M |
| August 13, 2026 | 26.23M |
| August 12, 2026 | 26.62M |
| August 11, 2026 | 28.15M |
| August 10, 2026 | 28.53M |
| August 07, 2026 | 29.17M |
| August 06, 2026 | 28.15M |
| August 05, 2026 | 28.40M |
| August 04, 2026 | 27.77M |
| Date | Value |
|---|---|
| August 03, 2026 | 25.98M |
| July 31, 2026 | 26.23M |
| July 30, 2026 | 26.49M |
| July 29, 2026 | 24.70M |
| July 28, 2026 | 25.85M |
| July 27, 2026 | 28.28M |
| July 24, 2026 | 27.77M |
| July 23, 2026 | 29.30M |
| July 22, 2026 | 28.91M |
| July 21, 2026 | 30.19M |
| July 20, 2026 | 30.32M |
| July 17, 2026 | 29.30M |
| July 16, 2026 | 29.81M |
| July 15, 2026 | 32.23M |
| July 14, 2026 | 31.85M |
| July 13, 2026 | 36.82M |
| July 10, 2026 | 38.61M |
| July 09, 2026 | 35.42M |
| July 08, 2026 | 32.23M |
| July 07, 2026 | 38.23M |
| July 06, 2026 | 42.82M |
| July 02, 2026 | 43.33M |
| July 01, 2026 | 43.97M |
| June 30, 2026 | 45.88M |
| June 29, 2026 | 39.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.072M |
| Total Expenses (Quarterly) | 7.072M |
| EPS Diluted (Quarterly) | -0.5693 |
| Earnings Yield | -89.59% |
| Normalized Earnings Yield | -82.94 |